p27kip1: A new multiple endocrine neoplasia gene?

Neuroendocrinology

Volumn 93, Issue 1, 2011, Pages 19-28

  Marinoni, Ilaria ^a   Pellegata, Natalia S ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Cell cycle regulation; Multiple endocrine neoplasia; p27kip1

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E;

ARTICLE; CARCINOGENESIS; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; DOWN REGULATION; GENE CONTROL; GENE FUNCTION; GENE MUTATION; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR GENE;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MODELS, BIOLOGICAL; MULTIPLE ENDOCRINE NEOPLASIA;

EID: 79951672207     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320366     Document Type: Article

References (74)

1. Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-407.
2. Brandi ML, Gagel RF, Angeli A, et al: Guidelines for diagnosis and therapy of men type 1 and type 2. J Clin Endocrinol Metab 2001;86:5658-5671. (Pubitemid 33152604)
3. Mulligan LM, Kwok JB, Healey CS, et al: Germ-line mutations of the ret proto-oncogene in multiple endocrine neoplasia type 2a. Nature 1993;363:458-460. (Pubitemid 23179393)
4. Koch CA: Molecular pathogenesis of men2-associated tumors. Fam Cancer 2005;4:3-7. (Pubitemid 40754838)
5. Marx SJ, Stratakis CA: Multiple endocrine neoplasia: introduction. J Intern Med 2005;257:2-5.
6. Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Gozzini A, Luzi E, Brandi ML: Multiple endocrine neoplasia type 1. Orphanet J Rare Dis 2006;1:38.
7. Marini F, Falchetti A, Del Monte F, Carbonell Sala S, Tognarini I, Luzi E, Brandi ML: Multiple endocrine neoplasia type 2. Orphanet J Rare Dis 2006;1:45.
8. Lemos MC, Thakker RV: Multiple endocrine neoplasia type 1 (men1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008;29:22-32.
9. Lodish MB, Stratakis CA: Ret oncogene in men2, men2b, mtc and other forms of thyroid cancer. Expert Rev Anticancer Ther 2008;8:625-632. (Pubitemid 351818356)
10. Pellegata NS, Quintanilla-Martinez L, Siggelkow H, Samson E, Bink K, Hofler H, Fend F, Graw J, Atkinson MJ: Germ-line mutations in p27kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Sci USA 2006;103:15558-15563. (Pubitemid 44625631)
11. Georgitsi M, Raitila A, Karhu A, et al: Germline cdkn1b/p27kip1 mutation in multiple endocrine neoplasia. J Clin Endocrinol Metab 2007;92:3321-3325. (Pubitemid 47236408)
12. Agarwal SK, Mateo CM, Marx SJ: Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab 2009;94:1826-1834.
13. Molatore S, Marinoni I, Lee M, Pulz E, Ambrosio MR, Uberti EC, Zatelli MC, Pellegata NS: A novel germline cdkn1b mutation causing multiple endocrine tumors: clinical, genetic and functional characterization. Hum Mutat 2010, Epub ahead of print.
14. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: Cyclin e-cdk2 is a regulator of p27kip1. Genes Dev 1997;11:1464-1478.
15. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ: Forkhead transcription factor fkhr-l1 modulates cytokine-dependent transcriptional regulation of p27 (kip1). Mol Cell Biol 2000;20:9138-9148. (Pubitemid 32246103)
16. Servant MJ, Coulombe P, Turgeon B, Meloche S: Differential regulation of p27 (kip1) expression by mitogenic and hypertrophic factors: involvement of transcriptional and posttranscriptional mechanisms. J Cell Biol 2000;148:543-556.
17. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A: Enhanced ribosomal association of p27 (kip1) MRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997;272:7093-7098. (Pubitemid 27166413)
18. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-685.
19. Sherr CJ, Roberts JM: Cdk inhibitors: Positive and negative regulators of g1-phase progression. Genes Dev 1999;13:1501-1512. (Pubitemid 29297917)
20. Kamura T, Hara T, Matsumoto M, Ishida N, Okumura F, Hatakeyama S, Yoshida M, Nakayama K, Nakayama KI: Cytoplasmic ubiquitin ligase kpc regulates proteolysis of p27 (kip1) at g1 phase. Nat Cell Biol 2004;6:1229-1235. (Pubitemid 39625122)
21. Ishida N, Hara T, Kamura T, Yoshida M, Nakayama K, Nakayama KI: Phosphorylation of p27kip1 on serine 10 is required for its binding to crm1 and nuclear export. J Biol Chem 2002;277:14355-14358. (Pubitemid 34952496)
22. Carrano AC, Eytan E, Hershko A, Pagano M: Skp2 is required for ubiquitin-mediated degradation of the cdk inhibitor p27. Nat Cell Biol 1999;1:193-199. (Pubitemid 129500937)
23. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P: Promoting apoptosis: a novel activity associated with the cyclin-dependent k inase inhibitor p27. Cancer Res 1997;57:5441-5445. (Pubitemid 28006743)
24. Nickeleit I, Zender S, Sasse F, et al: Argyrin a reveals a critical role for the tumor suppressor protein p27 (kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell 2008;14:23-35. (Pubitemid 351885496)
25. Hiromura K, Pippin JW, Fero ML, Roberts JM, Shankland SJ: Modulation of apoptosis by the cyclin-dependent kinase inhibitor p27 (k ip1). J Clin Invest 1999;103:597-604. (Pubitemid 29122412)
26. Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM: P27kip1 modulates cell migration through the regulation of RhoA activation. Genes Dev 2004;18:862-876. (Pubitemid 38529656)
27. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF: Transduction of full-length tat fusion proteins into mammalian cells: Tat-p27kip1 induces cell migration. Nat Med 1998;4:1449-1452. (Pubitemid 28553472)
28. McAllister SS, Becker-Hapak M, Pintucci G, Pagano M, Dowdy SF: Novel p27 (kip1) c-terminal scatter domain mediates rac-dependent cell migration independent of cell cycle arrest functions. Mol Cell Biol 2003;23:216-228. (Pubitemid 36008515)
29. Goukassian D, Diez-Juan A, Asahara T, Schratzberger P, Silver M, Murayama T, Isner JM, Andres V: Overexpression of p27 (kip1) by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis. FASEB J 2001;15:1877-1885. (Pubitemid 32848791)
30. Sun J, Marx SO, Chen HJ, Poon M, Marks AR, Rabbani LE: Role for p27 (kip1) in vascular smooth muscle cell migration. Circulation 2001;103:2967-2972. (Pubitemid 32578136)
31. Diez-Juan A, Andres V: Coordinate control of proliferation and migration by the p27kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle cells and fibroblasts. Circ Res 2003;92:402-410. (Pubitemid 36298200)
32. Supriatno, Harada K, Kawaguchi S, Yoshida H, Sato M: Effect of p27kip1 on the ability of invasion and metastasis of an ora l cancer cell line. Oncol Rep 2003;10:527-532.
33. Nguyen L, Besson A, Heng JI, Schuurmans C, Teboul L, Parras C, Philpott A, Roberts JM, Guillemot F: P27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex. Genes Dev 2006;20:1511-1524. (Pubitemid 43830657)
34. Zhang P, Wong C, DePinho RA, Harper JW, Elledge SJ: Cooperation between the CDK inhibitors p27 (kip1) and p57 (kip2) in the control of tissue growth and development. Genes Dev 1998;12:3162-3167. (Pubitemid 28496261)
35. Bilodeau S, Roussel-Gervais A, Drouin J: Distinct developmental roles of cell cycle inhibitors p57kip2 and p27kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells. Mol Cell Biol 2009;29:1895-1908.
36. Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL: Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci USA 2005;102:749-754. (Pubitemid 40282737)
37. Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Hess JL, Meyerson M: Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell 2004;13:587-597. (Pubitemid 38299385)
38. Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK: Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27kip1 and p18ink4c. Proc Natl Acad Sci USA 2005;102:14659-14664. (Pubitemid 41457112)
39. Drosten M, Hilken G, Bockmann M, Rodicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Putzer BM: Role of men2a-derived ret in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 2004;96:1231-1239. (Pubitemid 39232714)
40. Medema RH, Kops GJ, Bos JL, Burgering BM: Afx-like forkhead transcription factors mediate cell-cycle regulation by ras and pkb through p27kip1. Nature 2000;404:782-787. (Pubitemid 30212408)
41. Joshi PP, Kulkarni MV, Yu BK, Smith KR, Norton DL, Veelen W, Hoppener JW, Franklin DS: Simultaneous downregulation of CDK inhibitors p18 (ink4c) and p27 (kip1) is required for MEN2a-ret-mediated mitogenesis. Oncogene 2007;26:554-570. (Pubitemid 46160969)
42. Slingerland J, Pagano M: Regulation of the CDK inhibitor p27 and its deregulation in ca ncer. J Cell Physiol 2000;183:10-17. (Pubitemid 30130220)
43. Chu IM, Hengst L, Slingerland JM: The CDK inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008;8:253-267. (Pubitemid 351430863)
44. Philipp-Staheli J, Payne SR, Kemp CJ: P27 (kip1): regulation and function of a haploinsufficient tumor suppressor and its misregulation in cancer. Exp Cell Res 2001;264:148-168. (Pubitemid 32989089)
45. Morosetti R, Kawamata N, Gombart AF, Miller CW, Hatta Y, Hirama T, Said JW, Tomonaga M, Koeffler HP: Alterations of the p27kip1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995;86:1924-1930.
46. Kawamata N, Morosetti R, Miller CW, et al: Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/kip1 in human malignancies. Cancer Res 1995;55:2266-2269.
47. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP: P27/kip1 mutation found in breast cancer. Cancer Res 1996;56:2400-2404. (Pubitemid 26154089)
48. Wlodarska I, Baens M, Peeters P, Aerssens J, Mecucci C, Brock P, Marynen P, Van den Berghe H: Biallelic alterations of both etv6 and cdkn1b genes in a t (12; 21) childhood acute lymphoblastic leukemia case. Cancer Res 1996;56:2655-2661. (Pubitemid 26170703)
49. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS, Gaudin PB, Fazzari M, Zhang ZF, Massague J, Scher HI: Distinct altered patterns of p27kip1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-1291. (Pubitemid 28433473)
50. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM: Decreased levels of the cell-cycle inhibitor p27kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-230. (Pubitemid 27064710)
51. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-234. (Pubitemid 27064711)
52. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 (kip1) - deficient mice. Cell 1996;85:733-744.
53. Park MS, Rosai J, Nguyen HT, Capodieci P, Cordon-Cardo C, Koff A: P27 and rb are on overlapping pathways suppressing tumorigenesis in mice. Proc Natl Acad Sci USA 1999;96:6382-6387. (Pubitemid 29256674)
54. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP: Pten and p27kip1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-224. (Pubitemid 32157454)
55. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ: The murine gene p27kip1 is haploinsufficient for tumour suppression. Nature 1998;396:177-180. (Pubitemid 28523620)
56. Fedele M, Pa lmieri D, Chiappetta G, Pasquinelli R, De Martino I, Arra C, Palma G, Valentino T, Pierantoni GM, Viglietto G, Rothstein JL, Santoro M, Fusco A: Impairment of the p27kip1 function enhances thyroid carcinogenesis in trk-t1 transgenic mice. Endocr Relat Cancer 2009;16:483-490.
57. Besson A, Assoian RK, Roberts JM: Regulation of the cytoskeleton: an oncogenic function for CDK inhibitors? Nat Rev Cancer 2004;4:948-955. (Pubitemid 39626218)
58. Besson A, Hwang HC, Cicero S, Donovan SL, Gurian-West M, Johnson D, Clurman BE, Dyer MA, Roberts JM: Discovery of an oncogenic act ivity in p27k ip1t hat causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007;21:1731-1746. (Pubitemid 47076473)
59. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM: Pkb/akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated g1 arrest. Nat Med 2002;8:1153-1160. (Pubitemid 35175971)
60. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL: Pkb/akt mediates cellcycle progression by phosphorylation of p27 (kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-1152. (Pubitemid 35175970)
61. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M: Cytoplasmic relocalization and inhibition of the cycli n-dependent k inase in hibitor p27 (kip1) by pkb/akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-1144. (Pubitemid 35175969)
62. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M: Oncogenic role of the ubiquitin ligase subunit skp2 in human breast cancer. J Clin Invest 2002;110:633-641. (Pubitemid 34988787)
63. Drobnjak M, Mela med J, Taneja S, Melzer K, Wieczorek R, Levinson B, Zeleniuch-Jacquotte A, Polsky D, Ferrara J, Perez-Soler R, Cordon-Cardo C, Pagano M, Osman I: Altered expression of p27 and skp2 proteins in prostate cancer of African-American patients. Clin Cancer Res 2003;9:2613-2619. (Pubitemid 36842104)
64. Qian X, Jin L, Kulig E, Lloyd RV: DNA methylation regulates p27kip1 expression in rodent pituitary cell lines. Am J Pathol 1998;153:1475-1482. (Pubitemid 28509904)
65. Yoshino A, Katayama Y, Ogino A, Watanabe T, Yachi K, Ohta T, Komine C, Yokoyama T, Fukushima T: Promoter hypermethylation profile of cell cycle regulator genes in pituitar y adenomas. J Neurooncol 2007;83:153-162. (Pubitemid 46784988)
66. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Claret FX, Grossman AB: Expression of phosphorylated p27 (kip1) protein and jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 2002;87:2635-2643. (Pubitemid 34655325)
67. Bamberger CM, Fehn M, Bamberger AM, Ludecke DK, Beil FU, Saeger W, Schulte HM: Reduced expression levels of the cell-cycle inhibitor p27kip1 in human pituitary adenomas. Eur J Endocrinol 1999;140:250-255. (Pubitemid 29155584)
68. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M, Coculescu M, Basu S, Grossman AB: Enhanced protein kinase B/akt signalling in pituitary tumours. Endocr Relat Cancer 2005;12:423-433. (Pubitemid 40896456)
69. Pellegata NS, Quintanilla-Martinez L, Keller G, Liyanarachchi S, Hofler H, Atkinson MJ, Fend F: Human pheochromocytomas show reduced p27kip1 expression that is not associated with somatic gene mutations and rarely with deletions. Virchows Arch 2007;451:37-46.
70. Canavese G, Azzoni C, Pizzi S, Corleto VD, Pasquali C, Davoli C, Crafa P, Delle Fave G, Bordi C: P27: a potential main inhibitor of cell proliferation in digestive endocrine tumors but not a marker of benign behavior. Hum Pathol 2001;32:1094-1101. (Pubitemid 33015670)
71. Grabowski P, Schrader J, Wagner J, Horsch D, Arnold R, Arnold CN, Georgieva I, Stein H, Zeitz M, Daniel PT, Sturm I: Loss of nuclear p27 expression and its prognostic role in relation to cyclin e and p53 mutation in gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res 2008;14:7378-7384.
72. Buchwald PC, Akerstrom G, Westin G: Reduced p18ink4c, p21cip1/waf1 and p27kip1 MRNA levels in tumours of primary and secondary hyperparathyroidism. Clin Endocrinol (Oxf) 2004;60:389-393. (Pubitemid 38297131)
73. Moeller SJ, Head ED, Sheaff RJ: P27kip1 inhibition of grb2-sos formation can regulate ras activation. Mol Cell Biol 2003;23:3735-3752. (Pubitemid 36597455)
74. Russo AA, Jeffrey PD, Patten AK, Massague J, Pavletich NP: Crystal structure of the p27kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 1996;382:325-331. (Pubitemid 26260452)